Reduced ubiquitin C-terminal hydrolase-1 expression levels in dementia with Lewy bodies

Neurobiology of Disease

Volumn 22, Issue 2, 2006, Pages 265-273

  Barrachina, Marta ^a   Castaño, Esther ^b   Dalfó, Esther ^a   Maes, Tamara ^c   Buesa, Carlos ^d   Ferrer, Isidro ^a,b  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c ORYZON GENOMICS   (Spain)

^d School of Pharmacy UB   (Spain)

Author keywords

synuclein; Dementia with Lewy Bodies; Parkinson's disease; Proteasome; UCHL

Indexed keywords

HYDROLASE; MESSENGER RNA; PROTEASOME; PROTEIN SUBUNIT; UBIQUITIN; UBIQUITIN C TERMINAL HYDROLASE 1; UNCLASSIFIED DRUG;

ADULT; AGE DISTRIBUTION; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN CORTEX; CARBOXY TERMINAL SEQUENCE; COMPARATIVE STUDY; CONTROLLED STUDY; DEMENTIA; DOWN REGULATION; FEMALE; FRONTAL CORTEX; HUMAN; HUMAN TISSUE; LEWY BODY; MALE; MEDULLA OBLONGATA; PARKINSON DISEASE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUBSTANTIA NIGRA; WESTERN BLOTTING;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BRAIN; CEREBRAL CORTEX; DOWN-REGULATION; FEMALE; HUMANS; LEWY BODIES; LEWY BODY DISEASE; MALE; MEDULLA OBLONGATA; MIDDLE AGED; NEURONS; PARKINSON DISEASE; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN SUBUNITS; RNA, MESSENGER; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA; UBIQUITIN; UBIQUITIN THIOLESTERASE;

EID: 33646482114     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2005.11.005     Document Type: Article

References (48)

1. Auburger G., Kessler K., Kang J.S., Gispert S., Stoltenburg G., and Braak H. Is the PARK5 I93M mutation a cause of Parkinson's disease with cognitive deficits and cortical Lewy Pathology? Abstracts 16th International Congress on Parkinson's Disease and Related Disorders, Berlin, June, 2005. Parkinsonism Rel. Disord. 11 Suppl. 2 (2005) 252
2. Auer H., Lyianarachchi S., Newsom D., Klisovic M.I., Marcucci G., and Kornacker K. Chipping away at the chip bias: RNA degradation in microarray analysis. Nat. Genet. 35 (2003) 292-293
3. Botchler M., Ditzel L., Groll M., Hartmann C., and Huber R. The proteasome. Annu. Rev. Biophys. Biomol. Struct. 28 (1999) 295-317
4. Braak, H., Braak, E., 1999. Temporal sequence of Alzheimer's disease related pathology. In: Peters, A., and Morrison, J.H. (Eds.), Neurodegenerative and age-related changes in structure and function of cerebral cortex. Kluwer Academic/Plenum Publishers. New York, Boston, Dordrecht, London, Moscow, pp. 475-512.
5. Braak H., Del Tredici K., Rüb U., de Vos R.A.I., Jansen Steur E.N.H., and Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24 (2003) 197-211
6. Choi J., Levey A.I., Weintraub S.T., Rees H.D., Gearing M., Chin L.S., and Li L. Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson's and Alzheimer's disease. J. Biol. Chem. 279 (2004) 13256-13264
7. Ciechanover A. The ubiquitin-proteasome pathway: on protein death and cell life. EMBO J. 17 (1998) 7151-7160
8. Dalfó E., Albasanz J.L., Martín M., and Ferrer I. Abnormal metabotropic glutamate receptor expression and signaling in the cerebral cortex in diffuse Lewy body disease is associated with irregular α-synuclein/phospholipase c (plcβ1) interactions. Brain Pathol. 14 (2004) 388-398
9. Forno L.S. Neuropathology of Parkinson's disease. J. Neuropathol. Exp. Neurol. 55 (1996) 259-272
10. Glickman M.H., and Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol. Rev. 82 (2002) 373-428
11. Groetrup M., Soza A., Eggers M., Kuehn L., Dick T.P., Schild H., et al. A role for proteasome regulator PA28α in antigen presentation. Nature 381 (1996) 166-168
12. Herschko A., and Ciechanover A. The ubiquitin system. Annu. Rev. Biochem. 67 (1998) 425-479
13. Ince P.G., and McKeith I. Dementia with Lewy bodies. In: Dickson D. (Ed). Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders (2003), ISN Neuropathol Press, Basel 188-199
14. Ince P.G., Perry E.K., and Morris C.M. Dementia with Lewy bodies. A distinct non-Alzheimer dementia syndrome?. Brain Pathol. 8 (1998) 299-324
15. Jellinger K.A., and Mizuno Y. Parkinson's disease. In: Dickson D. (Ed). Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders (2003), ISN Neuropathol Press, Basel 159-187
16. Kosaka K. Diffuse Lewy body disease in Japan. J. Neurol. 237 (1990) 197-204
17. Kosaka K. Dementia and neuropathology in Lewy body disease. Adv. Neurol. 60 (1993) 456-463
18. Kurihara L.J., Semenova E., Levorse J.M., and Tilghman S.M. Expression and functional analysis of Uch-L3 during mouse development. Mol. Cell. Biol. 7 (2000) 2498-2504
19. Kurihara L.J., Kikuchi T., Wada K., and Tilghman S.M. Loss of Uch-L1 and Uch-L3 leads to neurodegeneration, posterior paralysis and dysphagia. Hum. Mol. Genet. 10 (2001) 1963-1970
20. Lansbury P.T., and Brice A. Genetics of Parkinson's disease and biochemical studies of implicated gene products. Curr. Opin. Genet. Dev. 13 (2002) 299-306
21. Larsen C.N., Price J.S., and Wilkinson K.D. Substrate binding and catalysis by ubiquitin C-terminal hydrolases: identification of two active site residues. Biochemistry 35 (1996) 6735-6744
22. Larsen C.N., Krantz B.A., and Wilkinson K.D. Substrate specificity of de-ubiquitinating enzymes: ubiquitin C-terminal hydrolases. Biochemistry 37 (1998) 3358-3368
23. Leroy E., Boyer R., Auburger G., Leube B., Ulm G., Mezey E., Harta G., Brownstein M.J., Jonnalagada S., Chernova T., Dehejia A., Lavedan C., Gasser T., Steinbach P.J., Wilkinson K.D., and Plymeropoulos M.H. The ubiquitin pathway in Parkinson's disease. Nature 395 (1998) 451-452
24. Li J., and Rechsteiner M. Molecular dissection of the 11S REG (PA28) proteasome activators. Biochimie 83 (2001) 373-383
25. Liu Y., Fallon L., Lashuel H.A., Liu Z., and Lansbury P.T. The UCH-L1 gene encodes two opposing enzymatic activities that affect α-synuclein degradation and Parkinson's disease susceptibility. Cell 111 (2002) 209-218
26. Lowe J., McDermott H., Landon M., Mayer R.J., and Wilkinson K.D. Ubiquitin carboxyl-terminal hydrolase (PGP 9.5) is selectively present in ubiquitinated inclusion bodies characteristic of human neurodegenerative diseases. J. Pathol. 161 (1990) 153-160
27. Maraganore D.M., Farrer M.J., Hardy J.A., Lincoln S.J., McDonnell S.K., and Rocca W.A. Case-control study of the ubiquitin carboxy-terminal hydrolase L1 gene in Parkinson's disease. Neurology 53 (1999) 1858-1860
28. Maraganore D.M., Lesnick T.G., Elbaz A., Chartier-Harlin M.C., Gasser T., Kruger R., Hattori N., Mellick G.D., Quattrone A., Satoh J., Toda T., Wang J., Ionnidis J.P., de Andrade M., and Rocca W.A. UCHL-1 is a Parkinson's disease susceptibility gene. Ann. Neurol. 55 (2004) 512-521
29. McKeith I.G., Galasko D., Kosaka K., Perry E.K., Dickson D.W., Hansen L.A., Salmon D.P., Lowe J., Mirra S.S., Byrne E.J., Lennox G., Quinn N.P., Edwardson J.A., Ince P.G., Bergeron C., Burns E.J., Miller B.L., Lovestone S., Collerton D., Jansen E.N., Ballard C., de Vos R.A., Wilcock G.K., Jellinger K.A., and Perry R.H. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop. Neurology 47 (1996) 1113-1124
30. McKeith I.G., Ballard C.G., Perry R.H., Ince P.G., O'Brien J.T., Neill D., Lowery K., Jaros E., Barber R., Thompson P., Swann A., Fairbairn A.F., and Perry E.K. Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies. Neurology 54 (2000) 1050-1058
31. McNaught K.S., and Jenner P. Proteasomal function is impaired in substantia nigra in Parkinson's disease. Neurosci. Lett. 297 (2001) 191-194
32. McNaught K.S., and Olanow C.W. Proteolytic stress: a unifying concept for the etiopathogenesis of Parkinson's disease. Ann. Neurol. 53 (2003) S73-S84
33. McNaught K.S., Olanow C.W., Halliwell B., Isacson O., and Jenner P. Failure of the ubiquitin-proteasome system in Parkinson's disease. Nat. Rev., Neurosci. 2 (2001) 589-594
34. McNaught K.S., Mytilineou C., Jnobaptiste R., Yabut J., Shashidharan P., Jennert P., et al. Impairment of the ubiquitin-proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures. J. Neurochem. 81 (2002) 301-306
35. McNaught K.S., Belizaire R., Jenner P., Olanow C.W., and Isacson O. Selective loss of 20S proteasome alpha-subunits in the substantia nigra pars compacta in Parkinson's disease. Neurosci. Lett. 326 (2002) 155-158
36. McNaught K.S., Belizaire R., Isacson O., Jenner P., and Olanow C.W. Altered proteasomal function in sporadic Parkinson's disease. Exp. Neurol. 179 (2003) 38-46
37. Miller, R.M., Kiser, G.L., Kaysser-Kranich, T.M., Lockner, R.J., Palaniappan, C., Federoff, H.J., in press. Robust dysregulation of gene expression in substantia nigra and striatum in Parkinson's disease. Neurobiol. Dis.
38. Miura H., Oda K., Endo C., Yamazaki K., Shibasaki H., and Kikuchi T. Progressive degeneration of motor nerve terminals in GAD mutant mouse with hereditary sensory axonopathy. Neuropathol. Appl. Neurobiol. 19 (1993) 41-51
39. Mukoyama M., Yamazaki K., Kikuchi T., and Tomita T. Neuropathology of gracile axonal dystrophy (GAD) mouse. An animal model of central distal axonopathy in primary sensory neurons. Acta Neuropathol. 79 (1989) 294-299
40. Nishikawa K., Li H., Kawamura R., Osaka H., Wang Y.L., Hara Y., Hirokawa T., Manago Y., Amano T., Noda M., Aoki S., and Wada K. Alterations of structure and hydrolase activity of parkinsonism-associated human ubiquitin carboxyl-terminal hydrolase L1 variants. Biophys. Res. Commun. 304 (2003) 176-183
41. Oda K., Yamazaki K., Miura H., Shibasaki H., and Kikuchi T. Dying back type axonal degeneration of sensory nerve terminals in muscle spindles of the gracile axonal dystrophy (GAD) mutant mouse. Neuropathol. Appl. Neurobiol. 18 (1992) 265-281
42. Osaka H., Wang Y.L., Takada K., Takizawa S., Setsuie R., Li H., Sato Y., Nishikawa K., Sun Y.J., Sakurai M., Harada T., Hara Y., Kimura I., Chiba S., Namikawa K., Kiyama H., Noda M., Aoki S., and Wada K. Ubiquitin carboxy-terminal hydrolase L1 binds to and stabilizes monoubiquitin in neuron. Hum. Mol. Genet. 12 (2003) 1945-1958
43. Saigoh K., Wang Y.L., Suh J.G., Yamanishi T., Sakai Y., Kiyosawa H., Harada T., Ichihara N., Wakana S., Kikuchi T., and Wada K. Intragenic deletion in the gene encoding ubiquitin carboxy-terminal hydrolase in gad mice. Nat. Genet. 23 (1999) 47-51
44. Solano S.M., Miller D.W., Augood S.J., Young A.B., and Penney Jr. J.B. Expression of alpha-synuclein, parkin, and ubiquitin carboxy-terminal hydrolase L1 mRNA in human brain: genes associated with familial Parkinson's disease. Ann. Neurol. 47 (2000) 201-210
45. Spillantini M.G., Crowther R.A., Jakes R., Hasegawa M., and Goedert M. α-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 6469-6473
46. Tanaka K., and Tsurumi C. The 26S proteasome: Subunits and functions. Mol. Biol. Rep. 24 (1997) 3-11
47. Tofaris G.K., Razzaq A., Ghetti B., Lilley K.S., and Spillantini M.G. Ubiquitination of α-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function. J. Biol. Chem. 278 (2003) 44405-444011
48. Wilkinson K.D., Lee K.M., Deshpande S., Duerksen-Hughes P., Boss J.M., and Pohl J. The neuron-specific protein PGP 9.5 is a ubiquitin carboxyl-terminal hydrolase. Science 246 (1989) 670-673